Judith S Hecker is an expert in Hematology at Rechts der Isar Hospital (Germany). Judith S Hecker has authored 67 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 2 of them ongoing. SLR score: 223 (community average: 125). How the SLR is computed.

LeadR Profile

Judith S Hecker Rechts der Isar Hospital Germany
223 ScienceLeadR Reputation 223
Network Map

Hematology

Subspecialties: Oncology - Cardiology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2015 - 2026

Source: PubMed

Technical University of Munich

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 67

Citations

Citations: 584 1st author: 9 Last author: 2 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Plasma infrared molecular fingerprinting stratifies residual risk in coronary artery disease and reflects clonal haematopoiesis-associated biology.
PMID 42522903 — mortality, hematopoiesis, coronary artery disease, arteries, cardiology, secondary prevention, plasma
Eur Heart J Top journal20260
Proteomic and proteogenomic identification of targetable T-cell antigens in multiple myeloma.
PMID 42486677 — cells, neoplasms, proteogenomics, multiple myeloma, cell line, therapeutics, t-lymphocytes, ligands
Blood Adv20260
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
PMID 42321382 — cells, neoplasms, t-lymphocytes
Nat Med Top journal20261
Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation.
PMID 42317792 — cells, pregnancy, fertility, blood, parturition, hematologic neoplasms, fertility preservation, abortion, spontaneous, cryopreservation, therapeutics, live birth, t-lymphocytes, transplantation, car-t cell
EClinicalMedicine20260
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
PMID 42219399 — cells, safety, molecular biology, neutropenia, neoplasms, drug-related side effects and adverse reactions, t-lymphocytes
Nat Med Top journal20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 1 1
Phase 2 1
Phase 3 1

By status:

Active not recruiting 1
Recruiting 1
Unknown 1

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 2
multicentricup10 1

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
IMA401 TCER in Recurrent and or Refractory Solid Tumors Alone or in Combination With a Checkpoint Inhibitor
NCT05359445 — cells, safety, neoplasms, therapeutics, infusions, intravenous, t-lymphocytes
Phase 1Active not recruiting2022
tTF NGR Randomized Study STS
NCT05597917 — safety, saline solution, aminopeptidases, neoplasms, disease progression, drug therapy, contraindications, sarcoma, trabectedin, therapeutics, tissues, cd13 antigens, chemotherapy
Phase 3Recruiting2021

LeadR Networks

Main global connection map